AOD-9604, the growth-hormone fragment 176-191, and why the Phase 2 obesity readouts underdelivered

Key takeaways

• AOD-9604 is a synthetic analog of the C-terminal fragment of human growth hormone (residues 176-191) with an added N-terminal tyrosine. The native Cys182-Cys189 disulfide bridge from the parent GH molecule is preserved. It was developed by Metabolic Pharmaceuticals as an oral and subcutaneous obesity therapy. It is not FDA-approved .
• The preclinical rationale rested on the observation that the GH C-terminal fragment carries lipolytic and antilipogenic activity in adipocyte preparations without the glucose-perturbing or IGF-1-elevating activity of full-length growth hormone. Rodent diet-induced obesity work reported reductions in body weight and adipose mass .
• The human Phase 2b program in obese adults was a 12-week, randomized, double-blind, placebo-controlled trial in 536 participants. The placebo-adjusted weight difference was small (about 1.8 kg) and fell well short of the FDA's roughly 5 percent placebo-adjusted bar for obesity-drug approval; Metabolic Pharmaceuticals terminated the obesity development program in 2007 .
• AOD-9604 has been used in non-drug commercial contexts (a self-affirmed GRAS designation in the US has been claimed for food-ingredient applications), but that is a food-ingredient pathway, not an FDA-issued drug approval. There is no FDA-approved AOD-9604 indication for weight management .
• Community framing of AOD-9604 as a documented fat-loss peptide runs ahead of the human data. The rodent lipolytic mechanism is real; the human-outcome translation did not arrive.

What AOD-9604 actually is

AOD-9604 stands for anti-obesity drug 9604. The peptide is a synthetic analog of residues 176 through 191 of human growth hormone, the C-terminal region that biochemistry work in the 1990s identified as carrying the lipolytic activity of the full-length molecule. The synthetic construct preserves the native Cys182-Cys189 disulfide bridge from the parent GH molecule and adds an N-terminal tyrosine to the 15-residue native fragment. AOD-9604 was developed at Monash University by Frank Ng and colleagues and licensed to Metabolic Pharmaceuticals, an Australian biotech, which carried the molecule through preclinical and early-stage clinical development for obesity .

The pharmacological rationale was attractive on paper. Full-length growth hormone has been studied in obesity but is constrained by hyperglycemia, insulin resistance, and elevated IGF-1. The C-terminal lipolytic fragment retained the adipose-tissue activity of the parent molecule (in preclinical assays) without the glucose-perturbing activity, opening the possibility of a fat-loss therapy that avoided the GH-class adverse-event profile. Whether that selectivity survives in human physiology is the empirical question the Phase 2 program existed to answer.

What the preclinical program actually showed

Preclinical work in rodent diet-induced obesity models reported reductions in body weight and adipose tissue mass with subcutaneous and oral AOD-9604. Mechanistic studies described upregulation of beta3-adrenergic receptor expression in white adipose tissue and increased lipolysis with decreased lipogenesis, although later work in beta3-AR knockout mice indicated that the lipolytic effect does not strictly require direct beta3-AR signaling. The body of preclinical literature is reproducible across several independent groups and forms the basis of the lipolytic-mechanism claim that the molecule still carries in community discussion .

Phase 2 in obese adults: what the human trial actually showed

The pivotal human evidence for AOD-9604 comes from a 12-week, randomized, double-blind, placebo-controlled Phase 2b trial in obese adults sponsored by Metabolic Pharmaceuticals. The trial design tested subcutaneous AOD-9604 at multiple dose levels against placebo with body weight as the primary endpoint. Total enrollment was several hundred participants across active and placebo arms. The published outcome was that AOD-9604 did not produce clinically meaningful body weight reduction versus placebo at the doses and duration tested .

Subsequent shorter-duration trials and Metabolic Pharmaceuticals' own development pipeline did not yield a positive Phase 3 obesity readout. The company refocused on other indications (including a brief exploration of osteoarthritis-pain applications and oral formulations) without successfully advancing AOD-9604 to a regulatory approval. The molecule sits in the published evidence base as a preclinical success and a clinical failure on the obesity primary endpoint.

• Primary obesity endpoint in the Phase 2b trial was not met. AOD-9604 did not produce clinically meaningful weight loss versus placebo.
• Adverse event profile in the trial was generally similar to placebo. Tolerability was not the limiting factor; efficacy was.
• No Phase 3 obesity trial advanced to a successful regulatory readout.
• Comparator context matters. AOD-9604 was a development-stage candidate before the modern GLP-1 era; the relevant comparator now is semaglutide or tirzepatide at approved obesity doses, where the magnitude difference is large.

Why the rodent-to-human translation did not deliver

The most parsimonious explanation for the gap between rodent lipolytic activity and human weight-loss outcome is that the rodent-adipose-tissue assays measured one biochemical step (beta-adrenergic-pathway lipolysis in isolated adipocytes), while the human weight-management endpoint depends on a coordinated multi-tissue response including central appetite regulation, hepatic energy balance, hormonal control of satiety, and behavioral compensation. The C-terminal GH fragment may activate lipolysis without engaging the central appetite circuits that the modern GLP-1 class engages. Magnitude in adipose alone is not enough.

A second contributing factor is pharmacokinetic. AOD-9604 has a short circulating half-life and the human dosing schedules studied did not produce sustained adipose-tissue exposure at concentrations matching the in vitro work. A third factor is that the trial endpoints (12-week absolute weight change) are sensitive to background diet and adherence, and a modest pharmacological signal can be obscured by trial-population variance unless the effect size is large.

Research-vial AOD-9604 and current regulatory status

AOD-9604 has remained in circulation as a research-vial peptide product sold to the community after the obesity program lapsed. There is no FDA-approved AOD-9604 drug, and the FDA's posture on peptide bulk substances applies to research-vial preparations of AOD-9604 along with other research peptides. Identity, purity, dose accuracy, and sterility of community-sourced preparations cannot be assumed from the published trial program, which used regulated investigational supply .

AOD-9604 received limited recognition as a food-application ingredient in some jurisdictions outside the United States; that is a non-drug regulatory pathway. It does not establish efficacy as a weight-management therapy, and it does not create an FDA-approved drug indication in the US. Community claims that AOD-9604 has 'FDA approval' or 'safe for human use' status based on the food-application path are not accurate as a drug-regulatory statement.

What this means in 2026

AOD-9604 is one of several research peptides whose community reputation is partly built on a real but limited preclinical literature, partly on the legitimacy that an Australian biotech development program lent the molecule, and partly on persistence in the research-vial market. The published Phase 2 evidence in obese adults does not support a clinically meaningful weight-loss effect at the doses and durations tested. The modern obesity field has moved through tirzepatide, retatrutide, the higher-dose Wegovy program, and the CagriSema combination; the bar for any fat-loss peptide claim now sits roughly an order of magnitude higher than where AOD-9604 landed.

For research and educational purposes only. Not medical advice. The honest framing of AOD-9604 in 2026 is as a preclinical-success / clinical-failure case study in obesity drug development, not as a documented fat-loss therapy. Decisions about any weight-management therapy should involve a qualified clinician who can weigh approved options, contraindications, and individual context.

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.